Search
EHA-SfPM Precision Medicine Meeting
EHA and SfPM (Society for Functional Precision Medicine) are proud to present the first joint meeting on Precision Medicine.
Read moreTargeting the B-cell Receptor in Aggressive B-cell Lymphomas
In collaboration with Dr. Lou Staudt, Pharmacyclics and associate investigators, we performed a clinical trial of a very potent inhibitor of Bruton Tyrosine Kinase (BTK) called ibrutinib.
Read moreAddition of obinutuzumab (GA101) or rituximab to chlorambucil improves outcomes for elderly patients with chronic lymphocytic leukemia (CLL) and co-existing medical conditions (comorbidities)
CLL is the most common leukemia in the western world. Many CLL patients are elderly and have comorbidities rendering them ineligible for aggressive standard treatments.
Read moreExciting developments in Lymphoma (lymphnode cancer) and Myeloma (plasma cell cancer) to be presented at European Hematology Congress in Stockholm, June 13-16, 2013
Myeloma, until recently a fatal bone marrow malignancy with a short survival time, is now turning into a chronic disease.
Read moreEHA policy on double awarding
EHA is guided by the concept of supporting as many young investigators/clinicians as possible in their career development. Therefore, double awarding is not allowed. Winning an award excludes the award winner from winning another award while receiving the first.
Read moreMeet Willem Fibbe, our volunteer of the month
Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.
Meet Willem Fibbe, our volunteer of the month
Can you tell us what you do for EHA and when you started?
I have been involved in EHA over a period of twenty years, starting as counselor from 2000-2004.
Mission ‘Gene Therapy’ for Horizon Europe
Mission ‘Gene Therapy’ for Horizon Europe
Advanced therapies, such as gene therapy, hold promise for treating a wide range of chronic diseases and improving patients’ quality of life.
Ibrutinib improves survival in CLL and SLL patients: Results From the RESONATE Study.
Patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL) who experience short response duration or adverse cytogenetics have poor outcomes.
SWG Education Activities
Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).
Read more